基于胰岛素的益生菌输送系统增强肠道微生物群调节以缓解肠道感染
Sheng Wang1, Pingping Yuan1, Shijie Zhou1
1Animal-Derived Food Safety Innovation Team, College of Animal Science and Technology, Anhui Agricultural University, Hefei 230036, China.
Journal of agricultural and food chemistry
|September 3, 2025
概括
通过减少炎症和沙门氏菌感染来改善肠道健康. 这种益生菌系统增强有益细菌, 加强肠道屏障,
科学领域:
- 微生物学
- 免疫学
- 生物技术
背景情况:
- 抗生素破坏肠道微生物群,对肠道感染的有效性有限.
- 胃肠道复杂性和粘膜障碍对治疗构成挑战.
研究的目的:
- 使用乳清蛋白分离物和胰岛素开发一种载有基因素的纳米粒子 (Gen_Wi).
- 评估Gen_Wi在改善肠道微生物健康和对抗肠道感染方面的有效性.
主要方法:
- 使用乳清蛋白分离物和胰岛素合成了Gen_Wi纳米粒子.
- 在肠道上皮细胞中评估了Gen_ Wi对氧化应激和炎症的影响.
- 在体内评估了Gen_ Wi对沙门氏菌引起的肠损伤和肠道微生物群的影响.
- 机理分析涉及评估Nrf2/NF-κB通路和短链脂肪酸的产生.
主要成果:
- 通过激活Nrf2和抑制NF- kB通路,降低TNF- α和IL- 1β水平,Gen_ Wi减轻了氧化应激和炎症.
- 口服Gen_Wi使沙门氏菌的殖民减少了1000倍,恢复了杯状细胞,并增强了紧密结合蛋白.
- Gen_Wi重塑了肠道微生物群,促进有益的细菌和增加短链脂肪酸 (乙酸,酸盐,酸盐).
结论:
- Gen_Wi 作为一个益生菌系统,将益生菌功能与抗炎性质相结合.
- 通过调节宿主微生物相互作用和加强肠道屏障,Gen_Wi有效地对抗肠道感染.
- 这种新型纳米粒子系统为改善肠道微生物群的健康提供了有希望的方法.
相关概念视频
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
201
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
201
01:17Drugs for Treatment of Diarrhea-Predominant IBS
292
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
292
01:20Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
316
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
316
01:21Drugs for Treatment of Constipation-Predominant IBS
326
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
326
01:29Inflammatory Bowel Disease IV: Pharmacological Management
185
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
185